The 13 Price Pneumonia Vaccine Is On The Market. Can Watson Break The Monopoly Of Foreign Countries?

In November 19th, at the "2019 China Great Health Industry Summit" held in Guangzhou, Gongsun Qing, director of the human resources director and chief executive officer of Watson, said that Watson bio started from research and development. At present, Watson has six vaccine products on the market. In addition, there are heavy products, 13 valent pneumonia vaccines and HPV9 vaccines.

After the transformation of the vaccine industry, can domestic vaccine enterprises turn upside down?

As a modern high technology biopharmaceutical enterprise specializing in the development and production and sale of bio technology drugs such as human vaccines, Watson bio is building up an industrial platform in the field of modern biopharmaceutical industry and implementing the strategy of "import substitution" and "comprehensive internationalization".

According to public information, as of September 30th this year, Watson's total market capitalization was 41 billion 500 million yuan, ranking thirteenth in 773 GEM listed companies, and ranked eleventh in the 221 listed companies of the A share pharmaceutical sector. In March this year, Watson life was included in the MCSI index; in May, it was included in the FTSE Russell global stock index.

The big health industry forum has been held for three consecutive years, and has pioneered the quantitative indicators of CSR reports. Data map

Technological innovation leads industry reform

There are more than thirty vaccine manufacturers in China, and the third largest vaccine market in the world. However, the domestic vaccine market is facing many problems: small scale, high level of modernization and insufficient investment in scientific research. At the same time, most of the vaccines registered in China are traditional vaccines, and the development capacity of new-type vaccines is insufficient.

After the "Shandong vaccine" incident in 2016 and the "longevity vaccine" incident in 2018, the credibility of domestic vaccines dropped significantly. Meanwhile, the willingness of the public to vaccinated two valent vaccines decreased, which caused a great impact on the whole vaccine industry. In June this year, the People's Republic of China vaccine management act was adopted by the eleventh session of the thirteen NPC Standing Committee. This is the first time that China has increased the regulation of the vaccine industry to the legislative level. Meanwhile, the document mentioned the need to encourage innovation in vaccines, lay stress on basic research and industrial structure, and encourage exports to participate in international competition.

After the "longevity vaccine" incident, Watson's AC polysaccharide vaccine and DPT vaccine were selected as the national immunization plan designated supply varieties. When faced with danger, Watson creatures must have something extraordinary.

Watson's R & D investment has been at the top of the industry. According to public information, the proportion of Watson's investment in total revenue in the past ten years has been increasing continuously. In 2016, the proportion of company investment in revenue was 52.61%, 49.87% and 43.25% respectively in -2018. High R & D investment brings the same high returns.

Public information shows that Watson bio and its subsidiaries (Yuxi Watson and Ze run bio), as the state recognized enterprise technology center and national high-tech enterprises, have undertaken 5 national "863" plans, undertaking 7 major new drug innovation projects in 12th Five-Year, 6 new major drug innovation projects in 13th Five-Year, 63 patent applications, 32 authorized domestic authorized inventions, and 2 international PCT invention patents.

It is expected to break the monopoly.

At present, the important patent medicine market in China has been monopolized by foreign companies for a long time. After several years of research and development, Watson bio has broken dozens of patent protection of multinational companies and tackled difficult technical barriers.

Overall, the company has two independent research and development products very bright. The first is the 13 valent pneumococcal polysaccharide conjugate vaccine. The vaccine was completed in January 2018 and completed in September this year. It has been registered on-site inspection and GMP certification. After the successful launch of this vaccine, Watson bio will become the world's second and China's first listed company with 13 valent pneumonia vaccine products.

The two is the two valent HPV vaccine. The phase III clinical study has completed the collection of cases and entered the stage of blindness detection and statistical analysis. At present, the production workshop has been built and will be imported into the HPV vaccine in the future.

Once the two major products are put into operation, Watson will become the two largest global best selling vaccine company in China. Taking this opportunity, Watson bio is expected to fill the gaps in the current domestic vaccine and break the monopoly of foreign companies.

In fact, as early as before, Watson biological has been in line with international standards. The company is the first private vaccine company in China to be included in the national immunization program of foreign governments. It is also the only enterprise exporting the original vaccine to the United States. Last year, it received a purchase order contract from eight countries, including the United States, Indonesia, Egypt, Bangladesh, Philippines and Kyrgyzstan, with a sum exceeding US $25 million 700 thousand.

Although the vaccine industry is still a smaller sub industry in the modern medical field, it is a relatively high-end subdivision area in the field of biomedicine. In the future, with the further standardization of the vaccine market, the access threshold for the vaccine industry will be higher and higher. With the development of human disease spectrum, the demand for vaccines will continue to increase. It will play a more important role in disease prevention and treatment in the future, and the vaccine market is expected to further develop.